New analysis to be presented at EASD supports potential of Diamyd[®] to delay the progression of Stage 3 Type 1 Diabetes
A new retrospective analysis of clinical data from 241 individuals with Stage 3 Type 1 Diabetes carrying the HLA DR3-DQ2 genetic marker has been accepted for oral presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting in Vienna, Austria, 15-19 September. The analysis reinforces previous findings, demonstrating that treatment with Diamyd[®] (rhGAD65/alum), a precision medicine immunotherapy currently being evaluated in the pivotal Phase 3 trial DIAGNODE-3, leads to longer preservation of insulin production compared to placebo.The analysis combined data from